View Older Stories

Nov 14, 2025 07:12AM Trevi (TRVI) First to Show Positive IPF Chronic Cough, RCC Data - Cantor Fitzgerald

Nov 14, 2025 06:51AM Trevi Therapeutics (TRVI) PT Raised to $24 at Oppenheimer

Nov 14, 2025 05:57AM Trevi Therapeutics (TRVI) PT Raised to $21 at Clear Street

Nov 13, 2025 05:14PM Trevi Therapeutics (TRVI) files mixed shelf

Nov 13, 2025 04:12PM Trevi Therapeutics (TRVI) Tops Q3 EPS by 2c

Aug 27, 2025 03:21PM Trevi Therapeutics (TRVI) 15K contracts of September 7 calls trade as share price up 7.8%

Aug 21, 2025 04:40AM Morgan Stanley Starts Trevi Therapeutics (TRVI) at Overweight

Aug 7, 2025 04:22PM Trevi Therapeutics (TRVI) Tops Q2 EPS by 1c

Jul 1, 2025 06:48AM Cantor Fitzgerald Starts Trevi Therapeutics (TRVI) at Overweight

Jun 4, 2025 05:56AM Trevi Therapeutics (TRVI) Offering 17.4M Shares at $5.75

Jun 3, 2025 06:56AM H.C. Wainwright Reiterates Buy Rating on Trevi Therapeutics (TRVI)

Jun 3, 2025 06:26AM Stifel Reiterates Buy Rating on Trevi Therapeutics (TRVI)

Jun 2, 2025 04:03PM Trevi Therapeutics (TRVI) PT Raised to $23 at Oppenheimer

Jun 2, 2025 04:01PM Trevi Therapeutics (TRVI) Announces Proposed $100M Share Offering

Jun 2, 2025 12:18PM Trevi Therapeutics (TRVI) Falls to LOD, Down ~7pct, Raymond James: 'This is a clean win and Haduvio has now set the bar in IPF-CC'

Jun 2, 2025 07:00AM Trevi Therapeutics (TRVI) Announces Positive Topline Results from the Phase 2b CORAL Trial

May 28, 2025 06:45AM H.C. Wainwright Starts Trevi Therapeutics (TRVI) at Buy

May 21, 2025 09:03AM B.Riley on Trevi Therapeutics (TRVI): 'Remain Buyers into Imminent Ph2b CORAL Readout'

May 20, 2025 08:03AM Stifel Reiterates Buy Rating on Trevi Therapeutics (TRVI)

May 20, 2025 07:04AM Trevi Therapeutics (TRVI) Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

May 20, 2025 05:35AM Raymond James Reiterates Strong Buy Rating on Trevi Therapeutics (TRVI)

May 8, 2025 04:22PM Trevi Therapeutics (TRVI) Tops Q1 EPS by 4c

Apr 23, 2025 10:04AM Stifel Reiterates Buy Rating on Trevi Therapeutics (TRVI)

Mar 26, 2025 07:02AM Avalo Therapuetics (AVTX) Appoints Michael Heffernan as Chairman of the Board

Mar 19, 2025 07:22AM Raymond James Reiterates Strong Buy Rating on Trevi Therapeutics (TRVI)

Mar 19, 2025 07:13AM Stifel Reiterates Buy Rating on Trevi Therapeutics (TRVI)

Mar 19, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Trevi Therapeutics (TRVI)

Mar 18, 2025 04:05PM Trevi Therapeutics (TRVI) Tops Q4 EPS by 1c

Mar 11, 2025 06:42AM Trevi Therapeutics (TRVI) PT Raised to $12.50 at H.C. Wainwright

Mar 10, 2025 12:23PM Trevi Therapeutics (TRVI) PT Raised to $20 at Rodman & Renshaw

Mar 10, 2025 11:44AM Trevi Therapeutics (TRVI) PT Raised to $11 at Leerink Partners

Mar 10, 2025 07:46AM Stifel Reiterates Buy Rating on Trevi Therapeutics (TRVI)

Mar 10, 2025 07:21AM Raymond James Upgrades Trevi Therapeutics (TRVI) to Strong Buy, PT $29

Mar 10, 2025 07:13AM Trevi Therapeutics (TRVI) PT Raised to $25 at Needham

Mar 10, 2025 06:22AM Trevi Therapeutics (TRVI) Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio

Mar 6, 2025 02:04PM Clear Street Reiterates Buy Rating on Trevi Therapeutics (TRVI)

Feb 20, 2025 09:30AM Trevi Therapeutics (TRVI) PT Raised to $12 at Stifel

Jan 8, 2025 07:36AM Trevi Therapeutics (TRVI) PT Raised to $11 at B.Riley

Jan 8, 2025 07:33AM Trevi Therapeutics (TRVI) Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Dec 16, 2024 07:37AM Trevi Therapeutics (TRVI) Prices 12.5M Share Offering at $4/sh

Dec 12, 2024 07:30AM Trevi Therapeutics (TRVI) Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Pati

Dec 4, 2024 06:09AM Oppenheimer Reiterates Outperform Rating on Trevi Therapeutics (TRVI)

Dec 3, 2024 04:06PM Trevi Therapeutics (TRVI) Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Nov 6, 2024 04:34PM Trevi Therapeutics (TRVI) Misses Q3 EPS by 1c

Oct 22, 2024 06:59AM H.C. Wainwright Reiterates Buy Rating on Trevi Therapeutics (TRVI)

Oct 8, 2024 05:47AM Oppenheimer Reiterates Outperform Rating on Trevi Therapeutics (TRVI)

Oct 4, 2024 12:48PM B.Riley Reiterates Buy Rating on Trevi Therapeutics (TRVI)

Oct 4, 2024 07:48AM EF Hutton Reiterates Buy Rating on Trevi Therapeutics (TRVI)

Oct 3, 2024 04:11PM Trevi Therapeutics (TRVI) Provides Update on Haduvio's Clinical Development Program

Sep 30, 2024 05:42PM Trevi Therapeutics (TRVI) Appoints James V. Cassella as Chief Development Officer

View Older Stories